Multiple Myeloma Management vs SurvivorNet使用状況と統計

Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.
  • Apple App ストア
  • 無料
  • 医学

ストアランキング

- -

We believe far too many people still struggle to find information about treatments that can save their lives. SurvivorNet is closing this gap by creating a deep, video-based educational resource for patients featuring top physicians and researchers around the country. To create patient-focused educational content, the company is working with physicians at leading NCCN-designated cancer centers such as The National Cancer Institute, Dana-Farber, Memorial Sloan Kettering, Stanford, NYU, and M.D. Anderson.
  • Apple App ストア
  • 無料
  • ヘルス & フィットネス

ストアランキング

- -

Multiple Myeloma Management対SurvivorNetランキング比較

と過去28日間の Multiple Myeloma Management ランキング傾向を比較 SurvivorNet

ランキング

ご利用可能なデータがありません

Multiple Myeloma Management 対 SurvivorNet 国の比較によるランキング

と過去28日間の Multiple Myeloma Management ランキング傾向を比較 SurvivorNet

表示できるデータはありません

無料トライアルで任意のサイトと比較する

始める
Multiple Myeloma Management VS.
SurvivorNet

12月 19, 2024